Virbac Animal Health Reveals Q2 Sales Revenue

At constant currency rates, Virbac’s Q2 sales hit over €295 million, almost 2% more than the same time last year.

They experienced strong growth across the Asia Pacific and Europe, with an increase of 4.5% and 7% respectively. This made up for the Latin America region’s disappointing performance, dipping down by 11%, which was mostly down to Chile.

Virbac’s increase in Europe was largely fuelled by France, where business rapidly recovered, increasing by more than 21%, following a decrease in Q1. They also profited from the effects of the acquisition of a Czech distributor.

With the exception of China and India, whose performance has been fairly constant over the last 12 months, all of their Asia-Pacific regions are growing.

North American based operations are marginally increasing, but by less than 0.5%. This has been attributed to unexpected capacity constraints in production for canine and feline vaccinations, as well as the fallout from the cyberattack that took place in June.

The companion animal industry has not been performing quite at the same rate as it was last year, but strong growth in the petfood segment has compensated for short term challenges in the immunology. The ruminant industry has maintained the trajectory of the agricultural sector, which has made up for the fall in aquaculture.

They predict a steady sales increase of 0-4% as we move through the rest of the year.

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.